SEC Form 3 · accession 0001140361-26-037142
PDS Biotechnology Corp · PDSB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Janetta Trochimiuk
Officer — Principal Accounting Officer
Period of report
Sep 12, 2026
Accepted (ET)
Sep 18, 2026 · 4:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001472091
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 1,124 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.98 | holding | — | — | — | — | Jan 12, 2036 | Common Stock | 70,000 | — | D |
| Stock Option (Right to Buy)F2 | $1.79 | holding | — | — | — | — | Jun 12, 2035 | Common Stock | 30,000 | — | D |
| Stock Option (Right to Buy)F3 | $5.87 | holding | — | — | — | — | Feb 28, 2034 | Common Stock | 30,000 | — | D |
| Stock Option (Right to Buy)F4 | $11.61 | holding | — | — | — | — | Jan 4, 2033 | Common Stock | 25,000 | — | D |
| Stock Option (Right to Buy)F5 | $6.28 | holding | — | — | — | — | Jan 19, 2032 | Common Stock | 31,117 | — | D |
| Stock Option (Right to Buy)F5 | $2.43 | holding | — | — | — | — | Jun 17, 2031 | Common Stock | 27,750 | — | D |
| Stock Option (Right to Buy)F5 | $1.45 | holding | — | — | — | — | Jun 23, 2030 | Common Stock | 5,000 | — | D |
| Stock Option (Right to Buy)F5 | $2.88 | holding | — | — | — | — | Dec 9, 2029 | Common Stock | 10,000 | — | D |
Explanation of responses
- F1The option was granted on January 12, 2026, with 25% vesting on January 12, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
- F2The option was granted on June 12, 2025, with 25% vesting on June 12, 2026 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
- F3The option was granted on February 28, 2024, with 25% vesting on February 28, 2025 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
- F4The option was granted on January 4, 2023, with 25% vesting on January 4, 2024 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
- F5The options are fully vested and exercisable.